Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors. - Wikidata - awgldk - TriplyDB

Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors.

Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors.

http://www.wikidata.org/entity/Q34185133

about

Nicotinic receptor mechanisms and cognition in normal states and neuropsychiatric disorders.Synthesis of desformylflustrabromine and its evaluation as an alpha4beta2 and alpha7 nACh receptor modulator Mammalian nicotinic acetylcholine receptors: from structure to function Nootropic alpha7 nicotinic receptor allosteric modulator derived from GABAA receptor modulators Orthosteric and Allosteric Ligands of Nicotinic Acetylcholine Receptors for Smoking Cessation Cholinergic modulation by opioid receptor ligands: potential application to Alzheimer's disease Galanthamine and Non-competitive Inhibitor Binding to ACh-binding Protein: Evidence for a Binding Site on Non-α-subunit Interfaces of Heteromeric Neuronal Nicotinic Receptors Targeting α4β2 nicotinic acetylcholine receptors in central nervous system disorders: perspectives on positive allosteric modulation as a therapeutic approach.In Vivo Characterization of ARN14140, a Memantine/Galantamine-Based Multi-Target Compound for Alzheimer's Disease Cognitive deficits in schizophrenia: focus on neuronal nicotinic acetylcholine receptors and smoking.Free energy, precision and learning: the role of cholinergic neuromodulation.The effects of galantamine on nicotine withdrawal-induced deficits in contextual fear conditioning in C57BL/6 mice.Involvement of decreased muscarinic receptor function in prepulse inhibition deficits in mice reared in social isolation.Galantamine improves apomorphine-induced deficits in prepulse inhibition via muscarinic ACh receptors in mice Galantamine-induced amyloid-{beta} clearance mediated via stimulation of microglial nicotinic acetylcholine receptors Intranasal administration of acetylcholinesterase inhibitors.Upregulation of alpha7 Nicotinic Receptors by Acetylcholinesterase C-Terminal Peptides.The effects of galantamine on psychopathology in chronic stable schizophrenia.The Effects of an Uninterrupted Switch from Donepezil to Galantamine without Dose Titration on Behavioral and Psychological Symptoms of Dementia in Alzheimer's Disease.In search of allosteric modulators of a7-nAChR by solvent density guided virtual screening.Potential role of the combination of galantamine and memantine to improve cognition in schizophrenia Treatment of dementia with neurotransmission modulation.Acetylcholine receptor (AChR) α5 subunit variant associated with risk for nicotine dependence and lung cancer reduces (α4β2)₂α5 AChR function.Human α4β2 nicotinic acetylcholine receptor as a novel target of oligomeric α-synuclein.Methyllycaconitine- and scopolamine-induced cognitive dysfunction: differential reversal effect by cognition-enhancing drugs.Optimizing treatments for nicotine dependence by increasing cognitive performance during withdrawal.Effect of galantamine on the human alpha7 neuronal nicotinic acetylcholine receptor, the Torpedo nicotinic acetylcholine receptor and spontaneous cholinergic synaptic activity.Cognitive dysfunctions in schizophrenia: potential benefits of cholinesterase inhibitor adjunctive therapy.Allosteric modulators of the α4β2 subtype of neuronal nicotinic acetylcholine receptors.Positive allosteric modulators as an approach to nicotinic acetylcholine receptor-targeted therapeutics: advantages and limitations.Galanthamine plus estradiol treatment enhances cognitive performance in aged ovariectomized rats.Galantamine facilitates acquisition of hippocampus-dependent trace eyeblink conditioning in aged rabbits State-of-the-Art Automated Patch Clamp Devices: Heat Activation, Action Potentials, and High Throughput in Ion Channel Screening.Differential effects of acetylcholinesterase inhibitors on clinical responses and cerebral blood flow changes in patients with Alzheimer's disease: a 12-month, randomized, and open-label trial Sustaining high acetylcholine levels in the frontal cortex, but not retrosplenial cortex, recovers spatial memory performance in a rodent model of diencephalic amnesia Assessing the synergy between cholinomimetics and memantine as augmentation therapy in cognitive impairment in schizophrenia. A virtual human patient trial using quantitative systems pharmacology Cytotoxicity, nitric oxide and acetylcholinesterase inhibitory activity of three limonoids isolated from Trichilia welwitschii (Meliaceae).Galantamine, an acetylcholinesterase inhibitor and positive allosteric modulator of nicotinic acetylcholine receptors, attenuates nicotine taking and seeking in rats Alpha-7 nicotinic agonists for cognitive deficits in neuropsychiatric disorders: A translational meta-analysis of rodent and human studies.Potential acetylcholinesterase inhibitors: molecular docking, molecular dynamics, and in silico prediction.

P2860

Q24532028-E9E11536-4799-45F3-AFD6-A5B7E2F3DA96 Q24632272-C5A56133-BE59-485D-9A74-572E05327177 Q24647069-EDDAE051-6AE1-4F8E-B3E1-113F123081D4 Q24681828-28B3A90A-1A74-4ECE-BDBC-5326FDE663F5 Q26774830-DDEF11C4-1897-497E-9E6E-B36BCB5D998B Q26999066-DFE07E88-79FE-413C-8B41-3DE09DB68A70 Q27644708-849C3839-901B-4723-BFBC-1CD949C0B5FE Q27693356-4A113BBE-D619-4CAD-A9C5-5D1EDBA57549 Q28830911-A589A499-AF9C-4052-869F-2803E9A821A5 Q30396291-77D1FACF-3380-4242-A425-EC1C50C62769 Q30425844-4792104E-B9EE-4FD9-93BC-4734DD3257FF Q30463325-4D84045F-2FF3-4416-BD5F-C5BCE60BE5E6 Q30470845-F4DB7F46-F468-4E10-956D-4C375AD3F806 Q30484245-D5A73824-8985-436F-B796-E82223196236 Q30497637-C01C4382-F76B-4096-9C1D-5B62AA255CD7 Q33393915-E1025219-E1E3-4584-9415-FEBD564DF0BA Q33418312-FE374BAC-7F92-40B6-B9BE-D9DD76825AD9 Q33724801-92616233-278D-4D10-B1C2-D81672CB5080 Q33795194-9717AC13-7926-4483-A2D6-2E94609C13A8 Q33811917-7DC31812-BBBD-4A4D-A9FA-719F5B652D0F Q33905343-7C8B42B0-D65B-4C7F-968C-205D09EFA1AA Q34266258-DC909F02-4E70-4A68-A681-66D466E2888F Q34458445-29160942-2692-4EE5-AE89-4A1A98C810E1 Q34598256-2A363E0B-340D-4545-8F53-88491F2DA8BB Q34667088-345958D8-83DF-4243-8A36-283DC7401F0F Q34870758-F65F1C51-EA65-4FDC-9EAA-2112C2DE7B65 Q35048962-17255044-05AC-40F6-AFE8-5C16427C3145 Q35129327-8CCB5A10-DFDB-48CD-9FFE-F2879514EB7C Q35182101-628BCC6F-9472-4910-B9A7-C398BC3F6700 Q35182164-0E59159E-B848-4EF2-B983-7A01BBF68DE1 Q35534146-5A30A6F6-AE5D-4CAC-B275-1FA143AD4EA1 Q35541457-FB76DF26-E751-4478-BB8C-0E1671A75B38 Q35571158-1EEBDA10-F14F-4B22-9C9F-2F9422C3AF5E Q35631407-BE56CFB7-2790-495C-A846-86E2F2C4A5BE Q35859851-09FC2611-E4D7-4438-93E6-677B0D8A7113 Q36097637-6252D7BD-1E6E-4C97-A38B-8B2FD1F77076 Q36159257-457675AB-8AA6-4B34-A997-DCB1BFB5DF00 Q36174102-AF4DE901-9141-4A8D-A405-7C73DB92A01A Q36243977-3B597148-A3BE-415E-AE2F-971D5AED4C47 Q36276320-0A3DCD9F-9074-4E4F-8FC2-9F4849D51174

P2860

Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors.

http://www.wikidata.org/entity/Q34185133

description

2003 nî lūn-bûn

@nan

2003 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2003 թվականի մարտին հրատարակված գիտական հոդված

@hy

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

name

Galantamine is an allosterical ...... rinic acetylcholine receptors.

@ast

Galantamine is an allosterical ...... rinic acetylcholine receptors.

@en

Galantamine is an allosterical ...... rinic acetylcholine receptors.

@nl

type

label

Galantamine is an allosterical ...... rinic acetylcholine receptors.

@ast

Galantamine is an allosterical ...... rinic acetylcholine receptors.

@en

Galantamine is an allosterical ...... rinic acetylcholine receptors.

@nl

prefLabel

Galantamine is an allosterical ...... rinic acetylcholine receptors.

@ast

Galantamine is an allosterical ...... rinic acetylcholine receptors.

@en

Galantamine is an allosterical ...... rinic acetylcholine receptors.

@nl

P1433

Q34185133-AD02F968-81ED-4019-9D19-C5BA8F169465

P1476

Q34185133-FE7E7D20-A553-41FA-A116-0F1E12F0F372

P2093

Q34185133-0D5E28F5-2ADD-4189-8641-10345096DE9C

Q34185133-352C89EB-46B9-4763-A5F2-18473F22128F

Q34185133-616ABF61-83BE-4EDC-B2A5-9F08B023DB65

Q34185133-6646F999-E573-439B-B0B5-BEB82D70F293

Q34185133-79613899-BA6A-4E21-BEC7-36CEB31E524F

Q34185133-7AD73885-FDEE-4155-87B7-F3D6FC16F140

Q34185133-91C89709-6872-4A0D-A531-AEC7DDC700A2

Q34185133-94433A26-D585-49D5-9621-042389C07948

Q34185133-A4D50C4F-DA98-4889-9758-8892AC05F2E7

Q34185133-C52D6079-11FD-4DCC-A727-0B8176693917

P304

Q34185133-A5B4B978-79E5-4847-A975-91EAFD9804DB

P31

Q34185133-191094D6-5A4D-4C90-BEBC-ADA89CF85641

P356

Q34185133-AE7AEB65-EB05-48F6-AB78-88D5DE640228

P407

Q34185133-9FDCADAF-1C47-4E99-8335-E81060930662

P433

Q34185133-98F68A36-257C-4B30-B57F-1DDBE98B4803

P478

Q34185133-8E59B6C7-326B-41F9-9706-31CB22411647

P577

Q34185133-81543F2E-E59E-4187-B14D-41E09FBC5DAF

P5875

Q34185133-F315A10A-FC3F-4670-8E4A-0E036C9688DF

P698

Q34185133-573C8E04-9114-44EF-B896-CB1E13B94573

P356

JPET.102.045773

P1433

Journal of Pharmacology and Experimental Therapeutics

P1476

Galantamine is an allosterical ...... rinic acetylcholine receptors.

@en

P2093

Alfred Maelicke

http://www.w3.org/2001/XMLSchema#string

Andreas Fehrenbacher

http://www.w3.org/2001/XMLSchema#string

Anja Höffle

http://www.w3.org/2001/XMLSchema#string

Christoph Ullmer

http://www.w3.org/2001/XMLSchema#string

Claudia Christner

http://www.w3.org/2001/XMLSchema#string

Edna F R Pereira

http://www.w3.org/2001/XMLSchema#string

Edson X Albuquerque

http://www.w3.org/2001/XMLSchema#string

Hermann Lübbert

http://www.w3.org/2001/XMLSchema#string

Jürgen Ludwig

http://www.w3.org/2001/XMLSchema#string

Marek Samochocki

http://www.w3.org/2001/XMLSchema#string

P304

1024-1036

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1124/JPET.102.045773

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

305

http://www.w3.org/2001/XMLSchema#string

P577

2003-03-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

10845808

http://www.w3.org/2001/XMLSchema#string

P698

12649296

http://www.w3.org/2001/XMLSchema#string